Ova-Mit Warnings

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Warnings

General: Good levels of endogenous oestrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary oestrogen, or endometrial bleeding in response to progesterone) provide a favourable prognosis for ovulatory response induced by Ova-Mit. A low level of oestrogen, although clinically less favourable, does not preclude successful outcome of therapy. Ova-Mit therapy is ineffective in patients with primary pituitary or primary ovarian failure. Ova-Mit therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure, such as thyroid or adrenal disorders. For hyperprolactinaemia there is other preferred specific treatment. Ova-Mit is not first line treatment for low weight related amenorrhea, with infertility and has no value if a high FSH blood level is observed following an early menopause.

clomifene

Manufacturer:

Remedica

Distributor:

Corbridge